Cargando…

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

PURPOSE OF REVIEW: [(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arbuznikova, Daria, Eder, Matthias, Grosu, Anca-Ligia, Meyer, Philipp T., Gratzke, Christian, Zamboglou, Constantinos, Eder, Ann-Christin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640479/ https://www.ncbi.nlm.nih.gov/pubmed/37861915 http://dx.doi.org/10.1007/s11912-023-01458-6

Ejemplares similares

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
por: Eder, Ann-Christin, et al.
Publicado: (2021)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

[(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
por: Tönnesmann, Roswitha, et al.
Publicado: (2019)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2020)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Multimodal imaging for radiation therapy planning in patients with primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
por: Eder, Ann-Christin, et al.
Publicado: (2022)

Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition
por: Sachpazidis, Ilias, et al.
Publicado: (2020)

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment
por: Ilhan, Harun, et al.
Publicado: (2022)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
por: Zamboglou, Constantinos, et al.
Publicado: (2021)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2022)

Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
por: Zamboglou, Constantinos, et al.
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
por: Zschaeck, Sebastian, et al.
Publicado: (2018)

Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI—A Correlation Study With Whole Mount Histopathological Information as Reference
por: Kramer, Maria, et al.
Publicado: (2020)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
por: Szponar, Paweł, et al.
Publicado: (2023)

Intraindividual Comparison Between [(18)F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients
por: Marinescu, Ioana M., et al.
Publicado: (2022)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2019)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology
por: Gunashekar, Deepa Darshini, et al.
Publicado: (2022)

Comparison of Manual and Semi-Automatic [(18)F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference
por: Spohn, Simon K. B., et al.
Publicado: (2020)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Radiotherapy for nonagenarians: the value of biological versus chronological age
por: Sprave, Tanja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bi97cthmnuq40muvvk4silv0ea